We provide you with 20 years of free, institutional-grade data for SLDB stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of SLDB. Explore the full financial landscape of SLDB stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Ganot Ilan | Sale | -139 | $7.99 | $1,111 | 2024-01-30 |
| Ganot Ilan | Derivatives Exercise | 388 | 2024-01-30 | ||
| Ganot Ilan | Derivatives Exercise | 3,883 | 2024-01-30 | ||
| Koppel Adam | Grant, award...etc | 904,160 | $5.53 | 2024-01-12 | |
| RA CAPITAL MANAGEMENT, L.P. | Open Market Purchase | 904,160 | $5.53 | 2024-01-12 | |
| Bain Capital Life Sciences Investors, LLC | Grant, award...etc | 904,160 | $5.53 | 2024-01-12 | |
| PERCEPTIVE ADVISORS LLC | Open Market Purchase | 3,410,713 | $5.53 | 2024-01-12 | |
| Tan Kevin | Sale | -3,935 | $8.2 | $32,267 | 2024-01-11 |
| Tan Kevin | Derivatives Exercise | 11,250 | 2024-01-11 | ||
| SMITH IAN F | Derivatives Exercise | 15,570 | 2024-01-05 | ||
| Ganot Ilan | Sale | -1,142 | $5.3 | $6,052 | 2024-01-05 |
| Ganot Ilan | Derivatives Exercise | 2,993 | 2024-01-05 | ||
| Cumbo Alexander | Sale | -11,757 | $2.77 | $32,516 | 2023-12-05 |
| Cumbo Alexander | Derivatives Exercise | 28,612 | 2023-12-05 | ||
| Howton David T | Sale | -5,367 | $2.78 | $14,920 | 2023-12-05 |
| Howton David T | Derivatives Exercise | 13,051 | 2023-12-05 | ||
| Ganot Ilan | Derivatives Exercise | 1,583 | 2023-12-05 | ||
| Herzich Paul | Sale | -2,968 | $2.77 | $8,232 | 2023-12-05 |
| Herzich Paul | Derivatives Exercise | 7,238 | 2023-12-05 | ||
| Hanrahan Jessie | Sale | -4,879 | $2.78 | $13,562 | 2023-12-05 |
| Hanrahan Jessie | Derivatives Exercise | 11,862 | 2023-12-05 | ||
| Marlowe Jennifer | Sale | -4,890 | $2.77 | $13,525 | 2023-12-05 |
| Marlowe Jennifer | Derivatives Exercise | 11,888 | 2023-12-05 | ||
| SMITH IAN F | Derivatives Exercise | 15,569 | 2023-10-05 | ||
| Ganot Ilan | Derivatives Exercise | 1,583 | 2023-09-06 | ||
| SMITH IAN F | Derivatives Exercise | 15,570 | 2023-07-06 | ||
| Ganot Ilan | Sale | -487 | $4.85 | $2,364 | 2023-06-08 |
| Ganot Ilan | Derivatives Exercise | 1,553 | 2023-06-08 | ||
| Ganot Ilan | Derivatives Exercise | 1,583 | 2023-06-08 | ||
| SMITH IAN F | Derivatives Exercise | 15,569 | 2023-06-08 | ||
| Ganot Ilan | Derivatives Exercise | 1,584 | 2023-03-06 | ||
| Morris Carl Ashley | Sale | -441 | $7.49 | $3,303 | 2023-01-31 |
| Morris Carl Ashley | Derivatives Exercise | 1,233 | 2023-01-31 | ||
| Ganot Ilan | Sale | -141 | $7.49 | $1,056 | 2023-01-31 |
| Ganot Ilan | Derivatives Exercise | 388 | 2023-01-31 | ||
| Ganot Ilan | Sale | -1,382 | $7.49 | $10,351 | 2023-01-31 |
| Ganot Ilan | Derivatives Exercise | 3,883 | 2023-01-31 | ||
| SMITH IAN F | Derivatives Exercise | 1,620 | 2023-01-05 | ||
| PERCEPTIVE ADVISORS LLC | Grant, award...etc | 73,107 | 2022-12-06 | ||
| PERCEPTIVE ADVISORS LLC | Grant, award...etc | 2,528,656 | $7.05 | 2022-12-06 | |
| Cumbo Alexander | Grant, award...etc | 584 | 2022-12-05 | ||
| RA CAPITAL MANAGEMENT, L.P. | Grant, award...etc | 2,573,193 | $7.05 | 2022-12-05 | |
| SMITH IAN F | Grant, award...etc | 13,172 | 2022-12-05 | ||
| SMITH IAN F | Derivatives Exercise | 24,312 | 2022-10-04 | ||
| SMITH IAN F | Derivatives Exercise | 24,313 | 2022-07-06 | ||
| SMITH IAN F | Derivatives Exercise | 24,313 | 2022-04-05 | ||
| Morris Carl Ashley | Sale | -22,665 | $1.1 | $24,932 | 2022-03-15 |
| Schneider Joel Solomon Zev | Sale | -30,504 | $1.1 | $33,554 | 2022-03-15 |
| Ganot Ilan | Sale | -463 | $1.12 | $519 | 2022-03-08 |
The information provided in this report about SLDB stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Solid Biosciences Inc(NASDAQ:SLDB) 
Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expre...
Website: http://www.solidbio.com
Founded: 2013
Full Time Employees: 121
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic